Allison Ramiller

Allison Ramiller

Auto-generated profile, based on publicly available information

Allison Ramiller

Blue Note Therapeutics, San Francisco, CA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in JCO Oncology Practice
Verified
Journal Article
Open access
SZSean R. Zion
Sean R. Zion
CTChloe J. Taub
Chloe J. Taub
LHLauren C. Heathcote
Lauren C. Heathcote
ARAllison Ramiller
Allison Ramiller
STStacey Tinianov
Stacey Tinianov
DSDianne M. Shumay
Dianne M. Shumay
Results from a clinical trial of a new cognitive behavioral stress management (CBSM) app show a significant benefit for patients with cancer with symptoms of anxiety and depression. The double-blind, randomized controlled trial compared the cancer-specific app with a health education sham app in 449 patients diagnosed with nonmetastatic cancers. Patients who received the cancer-specific app showed significantly greater reductions in symptoms of anxiety and depression over 12 weeks and were significantly more likely to report their symptoms as much or very much improved at the end of the study. Self-reported adverse events were also collected to inform benefit-risk.

10 August 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
ARAllison Ramiller
Allison Ramiller
KMKathleen Mudie
Kathleen Mudie
ESElle Seibert
Elle Seibert
SWSadie Whittaker
Sadie Whittaker
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, complex, heterogeneous disease that affects millions and lacks both diagnostics and treatments. Big data, or the collection of vast quantities of data that can be mined for information, have transformed the understanding of many complex illnesses, such as cancer and multiple sclerosis, by dissecting heterogeneity, identifying subtypes, and enabling the development of personalized treatments. It is possible that big data can reveal the same for ME/CFS. Objective: This study aims to describe the protocol for the You + ME Registry, present preliminary results related to participant enrollment and satisfaction, and discuss the limitations of the registry as well as next steps. Methods: We developed and launched the You + ME Registry to collect longitudinal health data from people with ME/CFS, people with long COVID (LC), and control volunteers using rigorous protocols designed to harmonize with other groups collecting data from similar groups of people. Results: As of September 30, 2021, the You + ME Registry had over 4200 geographically diverse participants (3033/4339, 69.9%, people with ME/CFS; 833/4339, 19.2%, post–COVID-19 people; and 473/4339, 10.9%, control volunteers), with an average of 72 new people registered every week. It has qualified as “great” using a net promotor score, indicating registrants are likely to recommend the registry to a friend. Analyses of collected data are currently underway, and preliminary findings are expected in the near future. Conclusions: The You + ME Registry is an invaluable resource because it integrates with a symptom-tracking app, as well as a biorepository, to provide a robust and rich data set that is available to qualified researchers. Accordingly, it facilitates collaboration that may ultimately uncover causes and help accelerate the development of therapies. Trial Registration: ClinicalTrials.gov NCT04806620; https://clinicaltrials.gov/ct2/show/NCT04806620


26 January 2022 in JMIR Preprints
Verified
Preprint
Open access
ARAllison Ramiller
Allison Ramiller
KMKathleen Mudie
Kathleen Mudie
ESElle Seibert
Elle Seibert
SWSadie Whittaker
Sadie Whittaker
BACKGROUND ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) is a chronic, complex, heterogeneous disease that affects millions and lacks both diagnostics and treatments. Big data, or the collection of vast quantities of data that can be mined for information, has transformed the understanding of many complex illnesses like cancer [1,2] and multiple sclerosis [3,4], by dissecting heterogeneity, identifying subtypes, and enabling the development of personalized treatments. It is possible that big data can reveal the same for ME/CFS. OBJECTIVE To make ME/CFS and other post-infection diseases widely understood, diagnosable, and treatable. METHODS Solve M.E. developed and launched the You + ME Registry to collect longitudinal health data from people with ME/CFS, people with Long COVID (LC) and control volunteers using rigorous protocols designed to harmonize with other groups collecting data from similar groups of people. RESULTS The Registry now has over 4,200 geographically-diverse participants (3,033 people with ME/CFS, 833 post-COVID, and 473 control volunteers) with an average of 72 new people registered every week. It has qualified as "great" using a Net Promotor Score, indicating registrants are likely to recommend to a friend. Analyses of collected data are currently underway and preliminary findings are expected in the near future. CONCLUSIONS The Registry is an invaluable resource because it integrates with a symptom tracking app, as well as a biorepository, to provide a robust and rich dataset that is available to qualified researchers. Accordingly, it facilitates collaboration that may ultimately uncover causes and help accelerate the development of therapies.

19 August 2022 in JMIR Preprints
Verified
Preprint
Open access
ARAllison Ramiller
Allison Ramiller
KMKathleen Mudie
Kathleen Mudie
ESElle Seibert
Elle Seibert
SWSadie Whittaker
Sadie Whittaker
UNSTRUCTURED Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, complex, heterogeneous disease that affects millions and lacks both diagnostics and treatments. Big data, or the collection of vast quantities of data that can be mined for information, have transformed the understanding of many complex illnesses, such as cancer and multiple sclerosis, by dissecting heterogeneity, identifying subtypes, and enabling the development of personalized treatments. It is possible that big data can reveal the same for ME/CFS. This study aims to describe the protocol for the You + ME Registry, present preliminary results related to participant enrollment and satisfaction, and discuss the limitations of the registry as well as next steps. We developed and launched the You + ME Registry to collect longitudinal health data from people with ME/CFS, people with long COVID (LC), and control volunteers using rigorous protocols designed to harmonize with other groups collecting data from similar groups of people. As of September 30, 2021, the You + ME Registry had over 4200 geographically diverse participants (3033/4339, 69.9%, people with ME/CFS; 833/4339, 19.2%, post–COVID-19 people; and 473/4339, 10.9%, control volunteers), with an average of 72 new people registered every week. It has qualified as “great” using a net promotor score, indicating registrants are likely to recommend the registry to a friend. Analyses of collected data are currently underway, and preliminary findings are expected in the near future. The You + ME Registry is an invaluable resource because it integrates with a symptom-tracking app, as well as a biorepository, to provide a robust and rich data set that is available to qualified researchers. Accordingly, it facilitates collaboration that may ultimately uncover causes and help accelerate the development of therapies. Clinical Trials: ClinicalTrials.gov NCT04806620; https://clinicaltrials.gov/ct2/show/NCT04806620 DERR1-10.2196/36798